Chemical Structure (Inveltys 01)
Inveltys Suspension
Product Images NDC 71571-121
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Inveltys (NDC 71571-121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Alcon Laboratories, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Inveltys 02)
Figure 2 (Inveltys 03)
This appears to be a table showing the percentage of patients who experienced complete resolution of pain over a course of 15 days, with two time intervals (Day 4 and Day 8) for the W INVELTYS BID group and one time interval (Day 15) for the vehicle group. However, the "Grade" column is cut off and there is some error in the text.*
Principal Display Panel (2.8 mL Bottle Carton)
INVELTYS® Ophthalmic Suspension is a topical medication for application in the eye. Each mL of the suspension contains 10mg of Ioteprednol Etabonate (1%) and other inactive ingredients such as Glycerin, Sodium Citrate Dihydrate, Foloxamer 407, Sodium Chloride, Edetate Disodium Dihydrate, Citric Acid, and Water for Injection. The medication is manufactured for Kala Pharmaceuticals, Inc. and should be stored upright at 15°C 10 25°C (59°F 0 77°F). The package should not be frozen, and it is important to check if the tamper-evident overcap is intact before use. For more details on usage and dosage, please refer to the package insert.*
Inveltys 05
Inveltys 06
Inveltys 07
Inveltys 08
Inveltys 09
Inveltys 10
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
